-
公开(公告)号：US20220403052A1
公开(公告)日：2022-12-22
申请号：US17588094
申请日：2022-01-28
Applicant: AbbVie Inc.
Inventor： Jijie Gu , Dominic J. Ambrosi , Susan E. Lappe , Yingchun Li , Jonathan A. Hickson , Deanna L. Haasch , Supriya Gupta , Ravi Chari , Camellia Zamiri , Louie Naumovski , Xianhua Cao
IPC: C07K16/46 , A61K45/06 , C07K16/22 , A61K39/395 , A61K31/513 , A61K31/7068 , A61K31/337 , A61K31/4745 , A61K31/495 , A61K31/525 , C07K16/28
Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
-
公开(公告)号：US09469688B2
公开(公告)日：2016-10-18
申请号：US14822329
申请日：2015-08-10
Applicant: ABBVIE INC.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
IPC: C07H21/04 , C07K16/22 , C07K14/47 , C07K16/18 , A61K39/395 , A61K45/06 , C07K7/06 , C07K7/08 , A61K39/00
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
-
公开(公告)号：US09132190B2
公开(公告)日：2015-09-15
申请号：US14090778
申请日：2013-11-26
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
Abstract translation: 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫 包括多发性硬化的疾病。
-
4.发明申请ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF 有权ANTI-DLL4 / VEGF双变异型域免疫球蛋白及其用途公开(公告)号：US20140348835A1
公开(公告)日：2014-11-27
申请号：US14301546
申请日：2014-06-11
Applicant: AbbVie Inc.
Inventor： Jijie Gu , Dominic J. Ambrosi , Susan E. Lappe , Yingchun Li , Jonathan A. Hickson , Deanna L. Haasch , Supriya Gupta , Ravi Chari , Camellia Zamiri , Louie Naumovski , Xianhua Cao
IPC: C07K16/46 , A61K31/4745 , A61K31/525 , C07K16/28 , A61K31/7068 , A61K31/337 , A61K31/513 , C07K16/22 , A61K39/395 , A61K31/495
CPC classification number: C07K16/468 , A61K31/337 , A61K31/4745 , A61K31/495 , A61K31/513 , A61K31/525 , A61K31/7068 , A61K39/395 , A61K39/3955 , A61K39/39591 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K16/28 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94 , A61K2300/00
Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
Abstract translation: 本文公开了多价和多特异性结合蛋白，制备结合蛋白的方法及其在诊断，监测，抑制，预防和/或治疗癌症，肿瘤和/或其它血管发生依赖性疾病中的用途，所述疾病以异常DLL4为特征 和/或VEGF表达或活性。
-
公开(公告)号：US20180371071A1
公开(公告)日：2018-12-27
申请号：US15582065
申请日：2017-04-28
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
-
Patent Agency Ranking
公开(公告)号：US09550986B2
公开(公告)日：2017-01-24
申请号：US14136076
申请日：2013-12-20
Applicant: AbbVie, Inc.
Inventor： Feng Dong , Lorenzo Benatuil , Jijie Gu , Chung-Ming Hsieh
CPC classification number: C12N15/1089 , C07K16/465 , C40B30/02
Abstract: The present invention relates to improved methods for antibody engineering, e.g., humanization. In particular, the disclosure provides a high-throughput antibody humanization process that can be automated by computer-implementation.
Abstract translation: 本发明涉及用于抗体工程的改进方法，例如人源化。 具体地，本公开提供了可以通过计算机实现来自动化的高通量抗体人源化过程。
-
公开(公告)号：US20160060332A1
公开(公告)日：2016-03-03
申请号：US14822329
申请日：2015-08-10
Applicant: Abbvie Inc.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
IPC: C07K16/22
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
Abstract translation: 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫 包括多发性硬化的疾病。
-
公开(公告)号：US20190031783A1
公开(公告)日：2019-01-31
申请号：US15914856
申请日：2018-03-07
Applicant: AbbVie Inc.
Inventor： Jijie Gu , Dominic J. Ambrosi , Susan E. Lappe , Yingchun Li , Jonathan A. Hickson , Deanna L. Haasch , Supriya Gupta , Ravi Chari , Camellia Zamiri , Louie Naumovski , Xianhua Cao
IPC: C07K16/46 , C07K16/22 , A61K31/4745 , A61K31/495 , A61K31/513 , A61K31/525 , A61K31/7068 , A61K39/395 , A61K45/06 , A61K31/337 , C07K16/28 , A61K39/00
Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
-
公开(公告)号：US09944720B2
公开(公告)日：2018-04-17
申请号：US14845511
申请日：2015-09-04
Applicant: AbbVie Inc.
Inventor： Jijie Gu , Dominic J. Ambrosi , Susan E. Lappe , Yingchun Li , Jonathan A. Hickson , Deanna L. Haasch , Supriya Gupta , Ravi Chari , Camellia Zamiri , Louie Naumovski , Xianhua Cao
IPC: C07H21/04 , C12P21/06 , C12N1/12 , C12N1/20 , C12N15/00 , C12N5/00 , C07K16/46 , A61K45/06 , C07K16/22 , A61K39/395 , A61K31/513 , A61K31/7068 , A61K31/337 , A61K31/4745 , A61K31/495 , A61K31/525 , C07K16/28 , C07K16/00 , A61K39/00
CPC classification number: C07K16/468 , A61K31/337 , A61K31/4745 , A61K31/495 , A61K31/513 , A61K31/525 , A61K31/7068 , A61K39/395 , A61K39/3955 , A61K39/39591 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K16/28 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94 , A61K2300/00
Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
-
公开(公告)号：US09840554B2
公开(公告)日：2017-12-12
申请号：US15183725
申请日：2016-06-15
Applicant: ABBVIE INC.
Inventor： Jijie Gu , Diana Bowley , Lucia Eaton , Feng Dong , Lorenzo Benatuil , Tariq Ghayur , Ravi Chari , Matthew Rieser , Anca Clabbers
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K14/00 , C07K16/24 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/51 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Binding proteins that bind one or more of VEGF, PDGF and/or their receptors, including antibodies, CDR-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.027 seconds)
